Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.46 |
| ▸ | CNR2 | P34972 | 8/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.35 |
| ▸ | CBLB | Q13191 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136101 | 0.86 | PIM1 (0.37) | PIM1PIM3PIM2CNR2CBLB | |
| SCHEMBL25136133 | 0.86 | PIM1 (0.37) | PIM1PIM3PIM2CNR2CBLB | |
| SCHEMBL25136291 | 0.79 | TRPV3 (0.38) | PIM1PIM3PIM2CNR2 | |
| SCHEMBL25136270 | 0.79 | CNR2 (0.58) | CNR2KMT2A | |
| SCHEMBL25136288 | 0.79 | CNR2 (0.58) | CNR2KMT2A | |
| SCHEMBL25136122 | 0.78 | CD38 (0.37) | CNR2CBLBKDM4EGLAHTT | |
| SCHEMBL1711661 | 0.75 | KDM4E (0.51) | PIM1PIM3PIM2KDM4EGLA | |
| SCHEMBL17861724 | 0.75 | PIM1 (0.46) | PIM1PIM3PIM2KDM4EGLA | |
| SCHEMBL25136311 | 0.73 | CNR2 (0.38) | CNR2 | |
| SCHEMBL25135995 | 0.73 | CNR2 (0.38) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | PIM1 3631/4885PIM3 3552/4885PIM2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.